Hercules Capital
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 100
- Market Cap
- -
- Introduction
Hercules Capital, Inc. is a traded business development company, which invests in middle market companies located in the United States. The fund targets companies operating in the fields of life sciences, technology, SaaS Finance, and sustainable renewable energy. It provides equity, debt, loan, and mezzanine financing for buyouts, growth capital, and acquisitions capital requirements. The company was founded in December 2003 and is headquartered in San Mateo, CA.
Altimmune Secures $100 Million Credit Facility to Advance Pemvidutide Development for MASH and Alcohol-Related Disorders
Altimmune has secured a $100 million credit facility from Hercules Capital, with $15 million funded immediately and additional tranches available upon meeting clinical and financial milestones.
Axsome Therapeutics Secures $570 Million Credit Facility from Blackstone to Strengthen CNS Portfolio
Axsome Therapeutics has entered into a $570 million credit facility with Blackstone, expanding their available credit by over $200 million while significantly reducing capital costs.
VOQUEZNA Achieves $55.3M Revenue in First Full Year, Shows Strong Market Growth with 300,000 Prescriptions
Phathom Pharmaceuticals' VOQUEZNA generated $55.3 million in net revenue during 2024, with Q4 sales reaching $29.7 million, marking an 81% increase from Q3.
FDA Approves Phathom's Novel H. Pylori Treatments, Securing $260M Financing for Launch
Phathom Pharmaceuticals receives FDA approval for two vonoprazan-based combination therapies - Voquezna Triple Pak and Voquezna Dual Pak - for treating H. pylori infections.
Breakthrough Year in Multiple Sclerosis Research: Key Advances and Treatment Milestones in 2024
2024 marked significant progress in multiple sclerosis treatment and research, highlighted by the revision of McDonald diagnostic criteria and breakthrough clinical trials. Notable developments included positive results for tolebrutinib in non-relapsing SPMS and promising outcomes for ublituximab in treatment transitions, representing major steps forward in MS care.
Disc Medicine Secures $200M to Advance Clinical Trials of Hematologic Disease Therapies
Disc Medicine has obtained a $200 million non-dilutive term loan to support its clinical trials and enhance financial flexibility.